UNSPSC 51313103: Clocinizine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HQJ711KH8. European Medicines Agency schedules Clocinizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06685MIG. Clocinizine generally arises in the molecular formula C26H27CLN2. The term CLOCINIZINE is an International Non-Proprietary Name or INN. CLOCINIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule clocinizine under HS 29335995 and SITC 51576. As of Q4 2014, CLOCINIZINE remains the US FDA Preferred Term for this commodity. Clocinizine bears US NLM identifiers UMLS ID C1322002 and NCI Concept Code C77435. SMILES: CLC1CCC(C(N2CCN(CC2)C/C=C/C2CCCCC2)C2CCCCC2)CC1.

UNSPSC 51313103 Clocinizine is a Commodity code that in recent state and local procurement activity does not reflect purchases of clocinizine itself, but rather broader pharmaceutical and drug-related products and systems including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local health authorities, human services commissions, and cooperative purchasing alliances are the primary issuing bodies. The work solicited ranges from direct product procurement (naloxone and drug deactivation systems for community health initiatives) to strategic pharmacy benefit program design (direct-to-manufacturer prescription models) to cooperative multi-state pharmaceutical contracting serving state and local government facilities. Vendors typically must comply with drug supply chain security requirements, FDA manufacturing standards, E-Verify employment verification, and comprehensive insurance coverage including commercial general liability and professional liability.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring vendors to include shipping costs and maintain workers' compensation and commercial general liability coverage. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer pharmacy prescription programs, seeking vendor experience with self-insured employer contracting and value-based pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across Minnesota, Oregon, and participating jurisdictions through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and contract start July 1, 2026. Vendors must demonstrate cGMP and Drug Supply Chain Security Act compliance and maintain relationships with at least two authorized wholesalers.